Evidence-based medical evidence change of the payment limitation of antitumor drugs in national medical- insurance negotiation
- VernacularTitle:国家医保谈判抗肿瘤药品支付限定条件的循证医学证据变迁
- Author:
Shunlong OU
1
;
Jing LUO
2
;
Hui LIU
1
;
Jin DI
3
;
Qian JIANG
1
Author Information
1. Sichuan Cancer Hospital & Institute/Sichuan Cancer Center/School of Medicine，University of Electronic Science and Technology of China，Chengdu 610041，China
2. School of Medicine，University of Electronic Science and Technology of China，Chengdu 610041，China
3. Chengdu Healt hcare Security Administration Affairs Center，Chengdu 610041，China
- Publication Type:Journal Article
- Keywords:
national medical-insurance negotiation
- From:
China Pharmacy
2022;33(3):271-274
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To study the changes in medical-insuran ce payme nt limitations of anti tumor drugs in national medical- insurance negotiation （hereinafter referred to as “national negotiation ”）and recommendations of diagnosis and treatment guidelines corresponding to tumor issued by Chinese Society of Clinical Oncology （CSCO），so as to provide reference for the performance of national negotiation. METHODS The annual list of anti tumor drugs in national negotiation were summarized ；CSCO diagnosis and treatment guidelines were searched according to the tumor types restricted by the medical- insurance payment limitations of antitumor drugs in national negotiation ；the evidence evolution of the payment limitations of medical insurance for anti tumor drugs and CSCO diagnosis and treatment guidelines were analyzed quantitatively. RESULTS & CONCLUSIONS Finally，46 antitumor drugs in the agreement period were included ；seven of their payment limitations of medical insurance had changed ；and there were differences among the payment limitation of medical insurance ，drug labels and recommendations of CSCO diagnosis and treatment guidelines for 13 varieties；the recommendations ，strength of evidence ，recommendation level of CSCO diagnosis and treatment guidelines were changing for 28 varieties anti tumor drugs in different years ；the number of anti tumor drugs recommended by CSCO diagnosis and treatment guidelines differed significantly among different cancer varieties. The medical insurance payment limitations of anti tumor drugs in national negotiation have been gradually expanded ，and the corresponding recommendations ，strength of evidence， recommendation level in guidelines have been constantly improved. However ， the payment limitation of B-19-H-20200622） medical insurance for most drugs are limited to the indicationsof drug labels and drugs for some cancers are scarce ，such as 85420393。E-mail：oushunlong@sohu.com esophageal cancer and nasopharyngeal carcinoma.
